Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Sportradar (A): From Data to Storytelling
Casadesus-Masanell, Ramon; Elterman, Karen; Gassmann, OliverCaso HBS-719429-EDirección estratégicaIn 2013, the Swiss sports data company Sportradar debated whether to expand from its core business of data provision to bookmakers into sports media products. Sports data was becoming a commodity, and in the future, sports leagues might reduce their dependence on third-party data feeds such as Sportradar's, prefering to develop data services in-house. Thus, CEO Carsten Koerl believed the company needed to branch into sports media, not just supply...Desde 8,20 €
-
Transatlantic Holdings, Inc. - The Belle of the Ball
Rose, Clayton; Sesia, AldoCaso HBS-313017-EIn November of 2011 Transatlantic Holdings, Inc., a global property and casualty reinsurance company, announced it had agreed to sell itself to Alleghany Corporation, ending "the most frenzied takeover battle" of 2011, which involved competitors, Warren Buffett's National Indemnity, and private equity investors. The agreement with Alleghany came after Transatlantic's failed effort at a merger of equals, and a several other unsuccessful bids for t...Desde 8,20 €
-
Switzerland: Foreign Pressure and Direct Democracy, Teaching Note
Rotemberg, Julio J.Nota del Instructor HBS-714007-EEconomíaTeaching Note for 712053.Desde 0,00 €
-
Innovation and Growth at Actelion Ltd.
Pisano, Gary P.; Beyersdorfer, Daniela; Dittrich, RuthCaso HBS-611065-ELiderazgo y Dirección de personasIn late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven organisation had grown into one of Europe's largest biotech firms by revenues. Their success was mainly founded on their orphan indication drug Tracleer, which Actelion sold and market...Desde 8,20 €
-
High Wire Act: Credit Suisse and Contingent Capital (B)
Rose, Clayton; Sesia, AldoCaso HBS-312008-EThe B case describes the process and terms of the very successful offerings of contingent capital in February 2011, as well as The Basel Committee's preliminary decision not to allow contingent capital to count as Tier 1 equity.Desde 5,74 €
-
Roll Back Malaria and BCG: the Change Initiative, Teaching Note
Ashraf, Nava; Kindred, NatalieNota del Instructor HBS-914041-ETeaching Note for 910023.Desde 0,00 €
-
Paratent Event Rentals Ltd.: The Job Costing Decision - Teaching Note
Matthew Sooy; Anthony MastromariniNota del Instructor IVEY-W24215-EContabilidad y controlTeaching note for product W24214.Desde 0,00 €
-
Post-Crisis Compensation at Credit Suisse (B)
Rose, Clayton; Sesia, AldoCaso HBS-311006-EThe (B) case describes how Credit Suisse management allocated the cost of the 25% U.K. banker's tax among shareholders, U.K. Managing Directors and the other employees globally.Desde 5,74 €
-
Swatch and the Global Watch Industry
Allen Morrison; Cyril BouquetCaso IVEY-9A99M023-EDirección estratégicaThe efforts of Swatch to reposition itself in the increasingly competitive global watch industry are reviewed in this case. Extensive information on the history and structure of the global watch industry is provided and the shrinking time horizons decision makers face in formulating strategy and in responding to changes in the industry are highlighted. In particular, the case discusses how technology and globalization have changed industry dynami...Desde 8,20 €
-
BabySupplies: Entrepreneur-Investor Conflict (C)
Ener, HakanCaso E-183-EÉtica empresarial y Responsabilidad Social Corporativa, Iniciativa emprendedoraThe peaceful period following the appointment of a new CEO is about to come to an end as FineWorks Venture Capital learns about Liz, the founder of BabySupplies, setting up an independent company operating in the same industry. What should FineWorks do in response?Desde 5,74 €